Problems liver cancer patients need to deal with

Share This Post

There are usually many problems that patients with liver cancer need to deal with, mainly including the following aspects:

1) To deal with the side effects of the body, most treatments for liver cancer will produce some side effects accordingly. Sometimes, the side effects can continue after the treatment is completed, and the doctors call them long-term side effects. Treatment of long-term side effects and late effects is an important part of survival care. Doctors will strive to prevent and alleviate the side effects of liver cancer patients. This kind of treatment belongs to the category of “palliative treatment”. Regardless of the patient’s age and disease stage, it is an important part of the treatment plan.

2) Coping with emotional and social impacts, after cancer diagnosis, will have a certain impact on patients’ emotional and social relationships and the body. Including negative emotions, such as sadness, anxiety or anger, stress, etc. Sometimes patients have problems expressing their feelings to their loved ones, or people do n’t know how to respond. At this time, patients and their families share their feelings with the doctor as much as possible.

3) In response to financial implications, cancer treatment can be expensive. It is often an important source of stress and anxiety for cancer patients and their families. In addition to the cost of treatment, many people find that they have everything related to their care. For some people, the high cost prevents them from following or completing their cancer treatment plan. This requires patients and families to come up with coping strategies, including combining other available resources to solve financial problems.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy